Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months
<p>Abstract</p> <p>Background</p> <p>Development and deployment of an effective malaria vaccine would complement existing malaria control measures. A blood stage malaria vaccine candidate, Merozoite Surface Protein-3 (MSP3), produced as a long synthetic peptide, has bee...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-07-01
|
| Series: | Malaria Journal |
| Online Access: | http://www.malariajournal.com/content/8/1/163 |
| _version_ | 1818497670042353664 |
|---|---|
| author | Segeja Method D Minja Daniel Rutta Acleus Sembuche Samwel Seth Misago Lemnge Martha Francis Filbert Msham Salum Gesase Samwel Lusingu John PA Bosomprah Samuel Cousens Simon Noor Ramadhani Chilengi Roma Druilhe Pierre |
| author_facet | Segeja Method D Minja Daniel Rutta Acleus Sembuche Samwel Seth Misago Lemnge Martha Francis Filbert Msham Salum Gesase Samwel Lusingu John PA Bosomprah Samuel Cousens Simon Noor Ramadhani Chilengi Roma Druilhe Pierre |
| author_sort | Segeja Method D |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Development and deployment of an effective malaria vaccine would complement existing malaria control measures. A blood stage malaria vaccine candidate, Merozoite Surface Protein-3 (MSP3), produced as a long synthetic peptide, has been shown to be safe in non-immune and semi-immune adults. A phase Ib dose-escalating study was conducted to assess the vaccine's safety and immunogenicity in children aged 12 to 24 months in Korogwe, Tanzania (ClinicalTrials.gov number: NCT00469651).</p> <p>Methods</p> <p>This was a double-blind, randomized, controlled, dose escalation phase Ib trial, in which children were given one of two different doses of the MSP3 antigen (15 μg or 30 μg) or a control vaccine (Engerix B). Children were randomly allocated either to the MSP3 candidate malaria vaccine or the control vaccine administered at a schedule of 0, 1, and 2 months. Immunization with lower and higher doses was staggered for safety reasons starting with the lower dose. The primary endpoint was safety and reactogenicity within 28 days post-vaccination. Blood samples were obtained at different time points to measure immunological responses. Results are presented up to 84 days post-vaccination.</p> <p>Results</p> <p>A total of 45 children were enrolled, 15 in each of the two MSP3 dose groups and 15 in the Engerix B group. There were no important differences in reactogenicity between the two MSP3 groups and Engerix B. Grade 3 adverse events were infrequent; only five were detected throughout the study, all of which were transient and resolved without sequelae. No serious adverse event reported was considered to be related to MSP3 vaccine. Both MSP3 dose regimens elicited strong cytophilic IgG responses (subclasses IgG1 and IgG3), the isotypes involved in the monocyte-dependant mechanism of <it>Plasmodium falciparum </it>parasite-killing. The titers reached are similar to those from African adults having reached a state of premunition. Furthermore, vaccination induced seroconversion in all vaccinees.</p> <p>Conclusion</p> <p>The MSP3 malaria vaccine candidate was safe, well tolerated and immunogenic in children aged 12–24 months living in a malaria endemic community. Given the vaccine's safety and its induction of cytophilic IgG responses, its efficacy against <it>P. falciparum </it>infection and disease needs to be evaluated in Phase 2 studies.</p> |
| first_indexed | 2024-12-10T18:48:07Z |
| format | Article |
| id | doaj.art-2b11ac9b0d22418fb7125a749df2a7b8 |
| institution | Directory Open Access Journal |
| issn | 1475-2875 |
| language | English |
| last_indexed | 2024-12-10T18:48:07Z |
| publishDate | 2009-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Malaria Journal |
| spelling | doaj.art-2b11ac9b0d22418fb7125a749df2a7b82022-12-22T01:37:25ZengBMCMalaria Journal1475-28752009-07-018116310.1186/1475-2875-8-163Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 monthsSegeja Method DMinja DanielRutta AcleusSembuche SamwelSeth MisagoLemnge MarthaFrancis FilbertMsham SalumGesase SamwelLusingu John PABosomprah SamuelCousens SimonNoor RamadhaniChilengi RomaDruilhe Pierre<p>Abstract</p> <p>Background</p> <p>Development and deployment of an effective malaria vaccine would complement existing malaria control measures. A blood stage malaria vaccine candidate, Merozoite Surface Protein-3 (MSP3), produced as a long synthetic peptide, has been shown to be safe in non-immune and semi-immune adults. A phase Ib dose-escalating study was conducted to assess the vaccine's safety and immunogenicity in children aged 12 to 24 months in Korogwe, Tanzania (ClinicalTrials.gov number: NCT00469651).</p> <p>Methods</p> <p>This was a double-blind, randomized, controlled, dose escalation phase Ib trial, in which children were given one of two different doses of the MSP3 antigen (15 μg or 30 μg) or a control vaccine (Engerix B). Children were randomly allocated either to the MSP3 candidate malaria vaccine or the control vaccine administered at a schedule of 0, 1, and 2 months. Immunization with lower and higher doses was staggered for safety reasons starting with the lower dose. The primary endpoint was safety and reactogenicity within 28 days post-vaccination. Blood samples were obtained at different time points to measure immunological responses. Results are presented up to 84 days post-vaccination.</p> <p>Results</p> <p>A total of 45 children were enrolled, 15 in each of the two MSP3 dose groups and 15 in the Engerix B group. There were no important differences in reactogenicity between the two MSP3 groups and Engerix B. Grade 3 adverse events were infrequent; only five were detected throughout the study, all of which were transient and resolved without sequelae. No serious adverse event reported was considered to be related to MSP3 vaccine. Both MSP3 dose regimens elicited strong cytophilic IgG responses (subclasses IgG1 and IgG3), the isotypes involved in the monocyte-dependant mechanism of <it>Plasmodium falciparum </it>parasite-killing. The titers reached are similar to those from African adults having reached a state of premunition. Furthermore, vaccination induced seroconversion in all vaccinees.</p> <p>Conclusion</p> <p>The MSP3 malaria vaccine candidate was safe, well tolerated and immunogenic in children aged 12–24 months living in a malaria endemic community. Given the vaccine's safety and its induction of cytophilic IgG responses, its efficacy against <it>P. falciparum </it>infection and disease needs to be evaluated in Phase 2 studies.</p>http://www.malariajournal.com/content/8/1/163 |
| spellingShingle | Segeja Method D Minja Daniel Rutta Acleus Sembuche Samwel Seth Misago Lemnge Martha Francis Filbert Msham Salum Gesase Samwel Lusingu John PA Bosomprah Samuel Cousens Simon Noor Ramadhani Chilengi Roma Druilhe Pierre Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months Malaria Journal |
| title | Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months |
| title_full | Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months |
| title_fullStr | Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months |
| title_full_unstemmed | Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months |
| title_short | Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months |
| title_sort | satisfactory safety and immunogenicity of msp3 malaria vaccine candidate in tanzanian children aged 12 24 months |
| url | http://www.malariajournal.com/content/8/1/163 |
| work_keys_str_mv | AT segejamethodd satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT minjadaniel satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT ruttaacleus satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT sembuchesamwel satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT sethmisago satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT lemngemartha satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT francisfilbert satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT mshamsalum satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT gesasesamwel satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT lusingujohnpa satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT bosomprahsamuel satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT cousenssimon satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT noorramadhani satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT chilengiroma satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months AT druilhepierre satisfactorysafetyandimmunogenicityofmsp3malariavaccinecandidateintanzanianchildrenaged1224months |